AUTHORS
Amanda Blackmon, DO, Brian John Ball, MD, MS2, Jianying Zhang, PhD3, Marjorie Robbins, PhD4, Tamer Othman, MD5, Sunmin Park, MD PhD6, Andrew Artz, MD,MS7, Anthony Selwyn Stein, MD8, Maria Cid, BSN9, Cindy Nguyen-Williams, MHA10, Wirlen Elame11, Tibor Kovacsovics, MD12, Long Gu13, Robert Hickey, PhD14, Le Xuan Truong Nguyen, PhD15, Guido Marcucci, MD16, Linda Malkas17
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Goodyear, Arizona, United States
13 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States, Translational Genomics Research Institute, Phoenix, Arizona, United States
16 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
ABSTRACT
Relapsed or refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR MDS) remain major unmet clinical needs with a lack of effective therapies and poor survival. The persistence of leukemia stem cells (LSC) with distinct mitochondrial metabolism is a mechanism of resistance to standard therapies including hypomethylating agents (HMAs) with or without venetoclax. Various types of LSCs have been described in patients with AML, as primitive or a distinct monocytic subtype of LSC found after resistance to venetoclax based therapies. Both primitive and monocytic LSCs rely on mitochondrial fusion (mitofusion), fatty acid oxidation (FAO), and oxidative phosphorylation (OXPHOS) for survival.
Cancer-associated proliferating cell nuclear antigen (caPCNA), a cancer-selective PCNA isoform, is highly expressed in AML LSCs but minimally expressed in normal hematopoietic stem cells (HSCs). Moreover, caPCNA expression is further increased in TP53-mutant and venetoclax-resistant AML compared with TP53-wild-type and venetoclax-sensitive disease, suggesting that caPCNA represents a therapeutic vulnerability in high-risk and treatment-resistant AML. We developed AOH1996, a novel, first-in-class, orally available small-molecule inhibitor of caPCNA. Our previous studies demonstrated that AOH1996 inhibits caPCNA, resulting in downregulation of the mitochondrial fusion regulator OPA1, disruption of mitochondrial fusion (mitofusion), suppression of FAO and OXPHOS, and ultimately inhibition of LSC growth (PMID: 39732733). AOH1996 is currently being evaluated in a first-in-human phase 1 clinical trial in patients with R/R AML and HR MDS (NCT06763341).
This is a single center, open label, phase 1 trial to assess safety and determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of AOH1996 in patients with R/R AML/HR MDS. Based on the safe dose level (DL) attained in an ongoing solid tumor trial (NCT05227326) at the time of protocol regulatory submission, and on efficacy in AML preclinical models, up to three DLs of AOH1996 oral (po) twice daily (bid) on days 1-28 of each 28 day cycle will be explored in the AML/HR MDS Arm: 600 mg (DL 1), 900 mg (DL2), and 1200 mg (DL 3). Key eligibility criteria include adults ≥ 18 years with R/R AML according to ICC or WHO and European Leukemia Network (ELN) 2022 or R/R HR MDS according to ICC or WHO and with International Prognostic Scoring System-Revised (IPSS-R) > 3.5 according to IWG 2023. Participants may remain on study for up to 6 cycles and can continue for up to 12 cycles if they achieve at least a partial response by the end of cycle 6.
Dose-limiting toxicities will be defined during the first cycle of therapy (28 days) as hematologic of any grade ≥ 3 ANC or platelets lasting > 7 days in absence of active disease, or non-hematologic grade 3 toxicities that don’t resolve by 72 hours, or non-hematologic grade 4 or 5 toxicities, unless clearly related to disease progression or intercurrent illness, according to the NCI CTCAE version 5.0. Exceptions are grade 3 fatigue, asthenia, constipation, anorexia, nausea, or vomiting not requiring tube feeding, parenteral nutrition, or requiring or prolonging hospitalization.
Dose escalation will occur according to a 3+3 design. The primary endpoint is safety. Secondary endpoints include overall response (CR, CRi, CRh, MLFS, and PR) by ELN 2022 response criteria for AML and CR (equivalent CR)+PR+CRL+CRh+HI by IWG 2023 response criteria for HR MDS, median time to first response, response duration, median and 1-year OS and EFS, pharmacokinetics, and pharmacodynamics correlative objectives (levels of OPA1, FAO, OXPHOS, glycolysis, LSC burden, caPCNA levels). The study is enrolling at City of Hope in Duarte and Orange County (Lennar) and at City of Hope in Phoenix and is currently enrolling participants on DL3 (1200 mg). This trial is registered on clinicaltrials.gov: NCT06763341.
A lower risk (LR) MDS Arm is planned once MTD/RP2D in the AML/HR MDS Arm is determined.
DISCLOSURES
Amanda Blackmon, DO: No relevant conflicts of interest to declare.